Noida, India: Imarc Group‘ latest study, Global Healthcare Cold Chain Logistics Market Report & Forecast (2011-2016), reveals that the increasing growth of the biosimilar (generic versions of branded biological drugs a) market is expected to expand the demand of cold chain logistic services in the coming years.
Overall, the total size of the healthcare cold chain logistic services market is expected to expand from its current figures of US$ 6.1 billion to nearly US$ 9.5 billion by 2016.
Findings from IMARC’s report suggest that biosimilars are expected to cost 20% – 60% less than their branded counterparts and, as a result, will become more affordable for both patients and healthcare providers. The study expects the entry of biosimilars to expand the overall patient pool of these drugs and thereby increasing their overall shipment volumes.
Findings also suggested that a number of key biosimilar manufacturers are expected to be based in Asian countries. Since the manufacturing facilities of these companies will be based in Asia and their end user markets in the US and Europe, the study expects a significant increase of biopharmaceutical exports between these regions.
